CMPX

Compass Therapeutics, Inc. (NASDAQ:CMPX) is a clinical-stage biopharmaceutical company founded in 2014 and headquartered in Boston, Massachusetts. The company went public in April 2021 and focuses on developing innovative antibody-based therapeutics for cancer treatment. As a pre-revenue biotechnology firm, Compass is currently advancing multiple drug candidates through various phases of clinical trials, with a particular emphasis on novel approaches to oncology treatment through bispecific antibodies and immune system modulators.